What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Regulatory Authorities and Scientific Consortia

Life Sciences, Clinical Trials, Pharmaceutical Regulation,
  • Thursday, October 24, 2019

Pharmacokinetic drug-drug interaction studies are in a state of transition—and there is often confusion around requirements and timing. They have transformed from studies of empirically-selected narrow therapeutic window and concomitantly-prescribed medications to systematic and mechanistic evaluations of a compound’s potential for interaction with key drug-metabolizing enzymes and transporters. This paradigm shift offers improved safety for participants in clinical trials and for patients after drug approval. An attractive incentive of these efforts for the industry is the development of robust in vitro systems and modelling approaches that eliminate the need for clinical drug-drug interaction studies in many cases.

Implementing these advances has been a daunting task for industry, academics and regulatory authorities. Regulators recognize the need for flexibility to accommodate an ever-expanding knowledge base in a timely manner. The US Food and Drug Administration (FDA) has released several draft guidances that reflected their current thinking on best practices for in vitro and clinical evaluations with the latest documents released in October 2017. Other regulatory authorities from around the world are actively focused on this issue and new regulatory guidance from the European Medicines Agency (EMA) is expected at any time.

This webinar will focus on recent scientific and regulatory developments on the design of clinical drug-drug interaction studies. Talking points will range from general concepts targeted towards scientists in drug development to specific recommendations from recent publications aimed at researchers directly involved in the design of clinical drug-drug interaction studies.

Key points to be discussed include:

  • Timing of drug-drug interaction studies
  • Which enzymes and transporters should be evaluated
  • The potential role of cocktail and microdosing drug-drug interaction studies
  • Selection of probe drugs and duration of dosing



Carol Collins, MD, Senior Clinical Pharmacologist, Medpace

Dr. Carol Collins has over 20 years of experience in drug-drug interactions including serving as associate medical director of a Phase I unit. She was a senior research scientist/clinical associate professor in the department of pharmaceutics at the University of Washington where she collaborated on the development of the Metabolism and Transport Drug Interaction Database and as co-investigator on clinical studies.

She received her MD from Ohio State University and is certified in regulatory affairs (RAC) and as a principal investigator (ACRP). She has co-authored numerous publications and presented at national and international conferences on this topic. She is currently a member of the American Society of Clinical Pharmacology and Therapeutics, the American Society for Pharmacology and Experimental Therapeutics, the American College of Clinical Pharmacology, the Association of Clinical Research Professionals and the American Association of Pharmaceutical Scientists.

Message Presenter

Who Should Attend?

This webinar will appeal to VPs, Directors, Managers and Department Heads working within:

  • Clinical Affairs
  • Clinical Research
  • Clinical Pharmacology
  • Clinical Outsourcing
  • Project Management
  • Regulatory Affairs
  • Medical Affairs

What You Will Learn

In this free webinar, attendees will learn about:

  • Timing of drug-drug interaction studies
  • Which enzymes and transporters should be evaluated
  • The potential role of cocktail and microdosing drug-drug interaction studies
  • Selection of probe drugs and duration of dosing

Xtalks Partner


Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,200 people across 37 countries.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account